Skip to main content
ARS Home » Southeast Area » New Orleans, Louisiana » Southern Regional Research Center » Cotton Structure and Quality Research » Research » Publications at this Location » Publication #329934

Research Project: Improved Quality Assessments of Cotton from Fiber to Final Products

Location: Cotton Structure and Quality Research

Title: Nanotechnology combined therapy: tyrosine kinase-bound gold nanorod and laser thermal ablation produce a synergistic higher treatment response of renal cell carcinoma in murine model

Author
item Liu, James - Tulane University
item Abshire, Caleb - Tulane School Of Medicine
item Carry, Connor - Tulane School Of Medicine
item Sholl, Andrew - Tulane University
item Mandava, Sree - Tulane University
item Datta, Amrita - Tulane School Of Medicine
item Ranjan, Manish - Tulane School Of Medicine
item Callaghan, Cameron - Tulane School Of Medicine
item Peralta, Donna
item Williams, Kristen - University Of New Orleans
item Lai, Weil - Tulane School Of Medicine
item Abdel-mageed, Asim - Tulane School Of Medicine
item Tarr, Matthew - University Of New Orleans
item Lee, Benjamin - Tulane University

Submitted to: BJU International
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 7/24/2016
Publication Date: 8/17/2016
Citation: Liu, J., Abshire, C., Carry, C., Sholl, A.B., Mandava, S.H., Datta, A., Ranjan, M., Callaghan, C., Peralta, D.V., Williams, K.S., Lai, W.R., Abdel-Mageed, A.B, Tarr, M., Lee, B.R. 2016. Nanotechnology combined therapy: tyrosine kinase-bound gold nanorod and laser thermal ablation produce a synergistic higher treatment response of renal cell carcinoma in murine model. BJU International. 119(2):342-348. https://doi.org/10.1111/bju.13590.
DOI: https://doi.org/10.1111/bju.13590

Interpretive Summary: Tyrosine kinase inhibitors (TKI) and gold nanorods (AuNR) were paired with nanoparticles with photothermal heating in a human metastatic clear cell renal cell carcinoma mouse model. Nanoparticles have been successful as a platform for targeted drug delivery in the treatment of urologic cancers. Likewise, the use of nanoparticles in photothermal tumor heating, though early in its development, has provided promising results. Our previous in vitro studies of nanoparticles loaded with both TKI and AuNR and paired with photothermal ablation have demonstrated significant synergistic cell kill greater than each individual arm alone. This study is a translation of our initial findings to an in vivo model.

Technical Abstract: Immunologically naïve nude mice (Athymic Nude-Foxn1nu) were injected bilaterally on the flanks (n=36) with 2.5 x 106 cells of a human metastatic renal cell carcinoma cell line (RCC 786-O). Subcutaneous xenograft tumors developed 1 cm palpable nodules. AuNR encapsulated in Human Serum Albumin (HSA) Protein nanoparticles were synthesized with or without a TKI and injected directly into the tumor nodule. Irradiation was administered with an 808 nm LED diode laser for six minutes. Animals were sacrificed 14 days post-irradiation; tumors were excised, formalin fixed, paraffin embedded, and evaluated for size and percent necrosis by a GU pathologist. Untreated contralateral flank tumors were used as controls. In mice that did not receive irradiation, TKI alone yielded 4.2% tumor necrosis on the injected side and administration of HSA-AuNR-TKI alone yielded 11.1% necrosis. In laser ablation models, laser ablation alone yielded 62% necrosis and when paired with HSA-AuNR had 63.4% necrosis. The combination of laser irradiation and HSA-AuNR-TKI had cell kill of 100%. In the absence of laser irradiation, TKI treatment alone or when delivered via nanoparticle produced moderate necrosis. Irradiation with and without gold particles alone also improves tumor necrosis. However, when irradiation is paired with gold particle and drug-loaded nanoparticle, the combination therapy demonstrated the most significant and synergistic complete tumor necrosis of 100% (p<0.05). This study illustrates the potential of combination nanotechnology as a new approach in the treatment of urologic cancers.